Inventor · disambiguated record
David Diller
Also filed as: DILLER DAVID · DILLER DAVID J
15 granted patents·13 pending applications·96 citations·filing 2000–2023
92Inventor score
Top patents by PatentIndex Score
28 records- 0190US7253174B2N-heterocyclic inhibitors of TNF-α expressionPHARMACOPEIA INC·Filed 2006·Granted Aug 7, 2007·15 cites·8 claims
- 0289US7902187B26-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppressionWYETH LLC·Filed 2008·Granted Mar 8, 2011·18 cites·12 claims
- 0388US7919490B26-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppressionWYETH LLC·Filed 2007·Granted Apr 5, 2011·17 cites·24 claims
- 0487US10030034B2Heterocycle amines and uses thereofLIGAND PHARM INC·Filed 2016·Granted Jul 24, 2018·5 cites·12 claims
- 0585US9266874B2Heterocycle amines and uses thereofLIGAND PHARM INC·Filed 2013·Granted Feb 23, 2016·2 cites·9 claims
- 0685US8044040B2N-heterocyclic inhibitors of TNF-alpha expressionBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Oct 25, 2011·6 cites·2 claims
- 0784US10604533B2Heterocycle amines and uses thereofLIGAND PHARM INC·Filed 2018·Granted Mar 31, 2020·1 cites·15 claims
- 0883US11186593B2Heterocycle amines and uses thereofLIGAND PHARM INC·Filed 2020·Granted Nov 30, 2021·1 cites·19 claims
- 0982US7951803B28-heteroarylpurine MNK2 inhibitors for treating metabolic disordersPHARMACOPEIA LLC·Filed 2007·Granted May 31, 2011·10 cites·20 claims
- 1076US11773110B2Heterocycle amines and uses thereofLIGAND PHARM INC·Filed 2021·Granted Oct 3, 2023·0 cites·11 claims
- 1176US7989459B2Purinones and 1H-imidazopyridinones as PKC-theta inhibitorsPHARMACOPEIA LLC·Filed 2007·Granted Aug 2, 2011·4 cites·19 claims
- 1274US7065453B1Molecular docking technique for screening of combinatorial librariesACCELRYS SOFTWARE INC·Filed 2000·Granted Jun 20, 2006·17 cites·2 claims
- 1368US2024254186A1GLP-1 Receptor Agonists Having Improved Pharmacological and Drug Delivery PropertiesDARBIX LLC·Filed 2023·Application pending·0 cites
- 1466US11883420B2Sting agonists for treating bladder cancer and solid tumorsVENENUM BIODESIGN LLC·Filed 2021·Granted Jan 30, 2024·0 cites·4 claims
- 1565US11161864B2Sting agonistsVENENUM BIODESIGN LLC·Filed 2019·Granted Nov 2, 2021·0 cites·18 claims
- 1663US11110106B2Sting agonists for treating bladder cancer and solid tumorsVENENUM BIODESIGN LLC·Filed 2020·Granted Sep 7, 2021·0 cites·20 claims
- 1761US2023015478A1Glp-1 receptor agonists having improved pharmacological and drug delivery propertiesRESOLUTE BIO INC·Filed 2022·Application pending·0 cites
- 1861US2022048936A1Novel sting agonistsVENENUM BIODESIGN LLC·Filed 2021·Application pending·0 cites
- 1953US2024228482A1Compounds, compositions and methods of treating cancerHOTSPOT THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2049US2009281075A1Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitorsPHARMACOPEIA INC·Filed 2008·Application pending·0 cites
- 2149US2003139435A1N-heterocyclic inhibitors of TNF-alpha expressionFiled 2002·Application pending·0 cites
- 2249US2011218189A1PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORSORGANON NV·Filed 2009·Application pending·0 cites
- 2346US2007078605A1Molecular docking technique for screening of combinatorial librariesDILLER DAVID J·Filed 2006·Application pending·0 cites
- 2445US2003228624A1Molecular docking methods for assessing complementarity of combinatorial libraries to biotargetsPHARMACOPEIA INC·Filed 2002·Application pending·0 cites
- 2543US2011046131A1Purines as pkc-theta inhibitorsORGANON AND PHARMACOPEIA LLC NV·Filed 2007·Application pending·0 cites
- 2642US2011230480A18-heteroarylpurine mnk2 inhibitors for treating metabolic disordersCOLE ANDREW G·Filed 2011·Application pending·0 cites
- 2739US2002025535A1Prioritization of combinatorial library screeningFiled 2001·Application pending·0 cites
- 2839US2006206269A1One-dimensional QSAR modelsPHARMACOPEIA DRUG DISCOVERY·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Diller files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →